GlobeNewswire by notified

AFARAK GROUP AND THE SHAREHOLDERS OF LL-RESOURCES GMBH HAVE ENTERED INTO AN AGREEMENT ON THE TERMINATION OF THE COMBINATION AGREEMENT AND THE CANCELLATION OF THE TRANSACTION

Share

Afarak Group SE        Inside information         12 October 2023 at 14:00 EET

AFARAK GROUP AND THE SHAREHOLDERS OF LL-RESOURCES GMBH HAVE ENTERED INTO AN AGREEMENT ON THE TERMINATION OF THE COMBINATION AGREEMENT AND THE CANCELLATION OF THE TRANSACTION

Afarak Group SE (“Afarak” or “Afarak Group”) and the shareholders of LL Resources GmbH (the “Sellers”) have today signed an agreement on the termination of the Combination Agreement (the “Termination Agreement”) and the cancellation of the transaction (the “Transaction”). The Termination Agreement and the cancellation of the Transaction entered into force immediately.

Afarak and the Sellers (together the “Parties”) signed a Combination Agreement (the “Combination Agreement”) on 11 May 2023 with certain conditions precedent in order to upon fulfilment of the conditions precedent execute the Transaction in which Afarak would have acquired all shares in LL-resources GmbH (“LLR”) by issuing 140,000,000 new shares of Afarak as consideration to the Sellers. The Annual General Meeting of Afarak have conditionally approved the Transaction on 21 June 2023.

During the completion process of the Transaction and the initial steps of the integration of LLR into Afarak Group, it became evident to the Parties that the anticipated synergy effects of the Transaction would not materialize in the way that was expected by the Parties. Hence, the mutual conclusion reached by the Parties was that the completion of the Combination Agreement would not bring sufficient synergy benefits to the shareholders of Afarak nor to the Sellers. Despite of the termination of the Combination Agreement and the Transaction, the Parties agree that they wish to continue developing the business relationship between Afarak and LLR also in the future.

Helsinki, 12 October 2023

AFARAK GROUP SE

Board of Directors

For additional information, please contact:

Thorstein Abrahamsen, Chairman of the Board, +4790924602, Thorstein.Abrahamsen@afarak.com

Financial reports and other investor information are available on the Company's website www.afarak.com.

Afarak Group is a specialist alloy producer focused on delivering sustainable growth with a Speciality Alloys business in southern Europe and a FerroAlloys business in South Africa. The Company is listed on NASDAQ Helsinki (AFAGR) and the Main Market of the London Stock Exchange (AFRK).

Distribution:
NASDAQ Helsinki
London Stock Exchange
Main media
www.afarak.com

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Azerion publishes Interim Unaudited Financial Results Q4 2023 and Preliminary Unaudited Financial Results Full Year 202328.2.2024 07:15:00 CET | Press release

Platform growth and improved efficiency driving performance in Q4 Highlights of Q4 2023 Net revenue of € 171.8 million, up 15.5% from € 148.8 million in Q4 2022, mainly driven by Platform Segment growth, particularly in advertising revenue from Direct sales, e-commerce and previous acquisitions including Hawk. Adjusted EBITDA of € 25.9 million, up 17.2% from € 22.1 million in Q4 2022 with margins improved due to increased Platform Segment revenue and contribution from Direct sales, continued integration of previous acquisitions and ongoing cost optimisation. Platform segment Adjusted EBITDA, of € 22.3 million, up 26.0% compared to € 17.7 million in Q4 2022, reflecting increased Net revenue and Platform efficiencies from optimisation and consolidation efforts. Increased the average digital ads sold per month by over 20% to approximately 12.9 billion in Q4 2023, up from approximately 10.7 billion in Q4 2022, driven by the integration of past acquisitions and the increased cross-selling o

Strong data from DSR® proof-of-concept studies in heart failure accepted for late-breaking presentation at THT 202428.2.2024 07:00:00 CET | Press release

Presentation by Key Opinion Leader Dr. Testani on Wednesday, March 6th 2024 Ghent, Belgium – 28 February 2024– Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "SequanaMedical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that the late-breaking abstract including data from the RED DESERT and SAHARA proof-of-concept studies of the Company’s DSR therapy in patients with diuretic-resistant heart failure have been selected for a late-breaking presentation at THT 2024. Technology and Heart failure Therapeutics (THT) will be held from March 4th to 6th, 2024 in Boston, US and is an international conference on the latest heart failure innovations, focusing on device- and technology-based treatments within the context of drug therapies. The abstract “Serial Direct Sodium Removal in Patients with Heart Failure and Diuretic Resistance” will be presented on Wednesday March 6th, 2024 by Dr. Jeffrey Testani, Associate Profe

12/2024・Trifork Holding AG – 2023 annual report and interim report for the quarter ending 31 December 202328.2.2024 07:00:00 CET | Press release

Trifork Holding AG Annual Financial Report Trifork Group – 2023 annual report and interim report for the quarter ending 31 December 2023 Company announcement no. 12 / 2024 Schindellegi, Switzerland – 28 February 2024 Trifork Group reports revenue growth of 12.4%for 2023 and 10.4% in Q4 2023 Full-year 2023 Trifork Group In 2023, Trifork Group revenue amounted to EURm 207.9, an increase of 12.4% from 2022. Organic growth was 9.3% driven by good activity in Digital Health, Smart Enterprise, Smart Building, and Cloud Operations. Inorganic growth of 3.1% came from the acquisitions of IBE and Chapter 5.Trifork Group EBITDA amounted to EURm 33.2, corresponding to 16.0% EBITDA margin.Trifork Group EBIT amounted to EURm 19.7, corresponding to 9.5% EBIT margin.Trifork Group net income amounted to EURm 17.4. Positive fair value adjustments in Trifork Labs of EURm 6.9 contributed to net income.Trifork Segment In 2023, adjusted EBITDA of the Trifork segment amounted to EURm 35.0, an increase of 9.7

Charlotte Hanneman to succeed Abhijit Bhattacharya as Philips’ Chief Financial Officer (CFO)28.2.2024 07:00:00 CET | Press release

February 28, 2024 Proposal to appoint Ms. Hanneman as member of Philips’ Board of Management fulfilling the role of CFO per October 1, 2024 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the proposal to appoint Charlotte Hanneman as member of the Board of Management, fulfilling the role of Chief Financial Officer (CFO), effective October 1, 2024. The proposal will be submitted to the Annual General Meeting of Shareholders (AGM), to be held on May 7, 2024. Ms. Hanneman will join Philips as a member of Philips’ Executive Committee on June 1, 2024, to start her induction and transition into the role, succeeding current CFO Abhijit Bhattacharya on October 1, 2024. Mr. Bhattacharya has been CFO and member of Philips’ Board of Management and Executive Committee since 2015 and will retire from the company after a successful 37-year career on September 30, 2024. Ms. Hanneman (Dutch, 1978) will join Philips with over 20 y

Idorsia and Viatris enter into a significant global research and development collaboration28.2.2024 07:00:00 CET | Press release

Ad hoc announcement pursuant to Art. 53 LR Viatris and Idorsia will collaborate on the global development and commercialization of two Phase 3 assets, selatogrel and cenerimod.Idorsia to receive an upfront payment of USD 350 million, potential development and regulatory milestone payments, additional sales milestone payments and tiered royalties on annual net sales.Viatris and Idorsia will both contribute to the development costs for both programs.Includes future optionality to expand collaboration with additional pipeline assets.Combines Viatris’ financial strength and worldwide operational infrastructure with Idorsia’s proven, highly productive drug development team and innovative engine. Allschwil, Switzerland – February 28, 2024 Idorsia Ltd (SIX: IDIA) today announced that it has entered into agreements for a significant global research and development collaboration with Viatris Inc. (NASDAQ: VTRS), a global healthcare company, for the global development and commercialization of tw

HiddenA line styled icon from Orion Icon Library.Eye